Aldeyra says its candidate won in chronic cough PhII, setting stage for bout with Merck, GSK

Aldeyra said that its ther­a­py re­duced cough fre­quen­cy in pa­tients with chron­ic cough in a Phase II study, as drug­mak­ers fo­cus on de­vel­op­ing treat­ments for a con­di­tion with no ap­proved ther­a­pies in the US or Eu­rope.

The biotech re­vealed topline da­ta Tues­day morn­ing for the drug, an oral RASP (re­ac­tive alde­hyde species) mod­u­la­tor, in a Phase II crossover tri­al. The pri­ma­ry end­point of the tri­al was safe­ty.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN